메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Singapore's First Professional 3x3 Basketball Team Reaches All-Time High in FIBA 3x3 World Rankings

Having reached world No. 35, Jumpshot SG continues to raise Singapore's 3x3 profile with blend of global talent, local ambition and youth development. SINGAPORE, Oct. 13, 2025 -- Jumpshot Singapore, the nation's first professional 3x3 basketball team, has reached a new milestone by climbing to #35 in the FIBA 3x3 Team Rankings, the highest-ever position achieved by a Singapore-based professional team. This breakthrough on the global stage underscores Jumpshot's growing competitiveness and its mission to professionalise 3x3 basketball in Singapore and the region. &nbs
- 황정호 기자
- 2025-10-13 10:00
PFPFA Donates $100,000 to The Straits Times School Pocket Money Fund, Raising an Additional $64,000 at Charity Night 2025

SINGAPORE, Oct. 13, 2025 -- PFPFA Singapore Pte Ltd ("PFPFA Singapore") hosted its annual Charity Night on 11 October 2025 at the Pan Pacific Singapore, announcing a $100,000 corporate donation to The Straits Times School Pocket Money Fund (STSPMF). In addition, a further $64,000 was raised during the event, reinforcing PFPFA's ongoing commitment to supporting children from low-income families through STSPMF's programmes and outreach efforts. Since its first Charity Night in 2007, PFPFA and its community of staff, wealth associates, associates, partners, and c
- 황정호 기자
- 2025-10-13 10:00
WIP Capital Investments Pty Ltd (ACN 686 632 066) Issues Offer Letter to Prospective Note Subscribers

[ 메디채널 황정호 기자 ] WIP Capital Investments Pty Ltd (ACN 686 632 066) as trustee for WIP Capital Investments Trust (the Issuer) MELBOURNE, Australia, Oct. 13, 2025 -- The Issuer would like to offer institutions the opportunity to participate as a noteholder under a loan note deed poll, dated as of 27 May 2025, as amended from time to time (the Loan Note Deed) in respect of notes to be issued by the Issuer under the Loan Note Deed, as described in more detail in the commercial terms sheet attached to this offer letter (the Notes). The proceeds of the Notes will be used by the Issuer to, a
- 황정호 기자
- 2025-10-13 09:42
As an academy even older than University of Cambridge, the great wisdom, "seeking truth from facts", took root here

CHANGSHA, China, Oct. 13, 2025 -- This is a report from Hunan Today: At the foot of Yuelu Mountain, Yuelu Academy's red gate stands with the old couplet "Only Chu Has Talents, and Here They Shine Most." Two young women in Hanfu—Ying and Shi—met American scholar Professor Xia (who's studied Hunan culture for 7 years) here. Xia explained the couplet's meaning and shared the academy's history: it's 300 years older than Oxford, and great minds like Zhu Xi and Mao Zedong once sought truth here. Ying asked Xia to guide them, and he agreed, changing into a scholar's robe. As an
- 김장윤(JASON KIM) 기자
- 2025-10-13 09:41
Smartee Launches World's First Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment

SHANGHAI, Oct. 13, 2025 -- Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an invisible alternative to conventional OSAHS treatment therapies, offering greater comfort and compliance, and improvi
- 김갑성 기자
- 2025-10-13 09:38
CARLSBERG ASIA AND GRAB CELEBRATE YEAR TWO OF PARTNERSHIP CHAMPIONING RESPONSIBLE DRINKING IN ASIA

SINGAPORE, Oct. 13, 2025 -- Carlsberg Asia and Grab, Southeast Asia's leading superapp, celebrated the second year of their strategic partnership on September 18, coinciding with Global Beer Responsible Day — an alliance that continues to reshape how consumers experience beer across the region. Launched in Q4 2024, the collaboration brings together digital innovation, premium beer experiences and enhanced consumer reach. In addition, both companies reinforced their shared commitment to promoting safe and responsible consumption across the region. Rooted in a shared vision to champion m
- 김장윤(JASON KIM) 기자
- 2025-10-13 09:30
Trip.com Group and Live Nation Asia Announce Strategic Partnership to Power Concert Travel

SINGAPORE, Oct. 13, 2025 -- Concert travel is reshaping tourism in Asia, with fans crossing borders and booking trips to see the artists they love. Trip.com Group, a global leader in travel services, and Live Nation Asia, the world's leading live entertainment company, have announced a multi-year strategic partnership to integrate travel and live music experiences across key Asian markets. Launching across Hong Kong/Macau, Singapore, Thailand, South Korea and Mainland China, the collaboration will allow fans to seamlessly plan concert-focused trips — combining exclusive
- 김장윤(JASON KIM) 기자
- 2025-10-13 09:00
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

[ 메디채널 김갑성 기자 ] EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines' proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas. In preclinical studies, EVM14 demonstrated the ability to induce immune memory and prevent tumor
- 김갑성 기자
- 2025-10-13 08:47
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ administration were approximately 80% and 70% greater than tirzepatide I.V. and SQ administration, respectively. - ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) in vitro. - ASC35 demonstrated approximately 71% greate
- 김갑성 기자
- 2025-10-13 08:10
Reach Surgical's OMNIBOT Performs First Urology Robotic Telesurgeries in Latin America

Advancing regional collaboration and surgeon training in remote robotic-assisted surgery SINGAPORE, Oct. 13, 2025 -- Reach Surgical, the Surgical Solutions division of Genesis MedTech, has facilitated the completion of two robotic telesurgeries using its OMNIBOT robotic-assisted system. Operating from Reach Surgical Institute (RSI) in Santiago, Dr. Roberto Vilches and Dr. Marcelo Kerkebe remotely performed a radical prostatectomy and a partial nephrectomy on patients at Meds Medical Center. These procedures mark an important milestone in advancing robotic t
- 김갑성 기자
- 2025-10-13 08:00

이전

91 92 93 94 95 96 97 98 99 100

많이 본 기사

최근기사

2025-11-03_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 17시 20분